{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:36:17Z","timestamp":1783985777823,"version":"3.55.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Bipolar Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory perception, as well as emotion- and self-processing are induced by stimulation of serotonin 2A receptors in cortical areas. The new paradigm of psychedelic-assisted psychotherapy suggests a therapeutic framework in which a safely conducted psychedelic experience is integrated into a continuous psychotherapeutic process. First randomized, controlled trials with psilocybin show promising efficacy, tolerability, and adherence in the treatment of unipolar depression. On the other hand, classic psychedelics seem to be associated with the induction of mania, which is an important issue to consider for the design of research and clinical protocols. So called atypical psychedelics are a heterogeneous group with overlapping subjective effects but different neurobiological mechanisms. Two examples of therapeutic value in psychiatry are 3,4-methyl\u200benedioxy\u200bmethamphetamine  (MDMA) and ketamine. Since 2020 the ketamine enantiomer esketamine has been granted international approval for treatment-resistant unipolar depression, and also first evidence exists for the therapeutic efficacy of ketamine in bipolar depression. Whether psychedelics will fulfil current expectations and find their way into broader clinical use will depend on future rigorous clinical trials with larger sample sizes. A well-considered therapeutic and legal framework will be crucial for these substances to create new treatment settings and a potential paradigm shift.<\/jats:p>","DOI":"10.1186\/s40345-022-00265-5","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:02:49Z","timestamp":1656997369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Psychedelics in the treatment of unipolar and bipolar depression"],"prefix":"10.1186","volume":"10","author":[{"given":"Oliver G.","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Halm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"265_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"265_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","volume":"7","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry. 2020;7:829\u201330.","journal-title":"Lancet Psychiatry"},{"key":"265_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CAJR. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542\u201355.","journal-title":"J Affect Disord"},{"key":"265_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02791072.2005.10399799","volume":"37","author":"JR BAKER","year":"2005","unstructured":"Baker JR. Psychedelic sacraments. J Psychoactive Drugs. 2005;37:179\u201387.","journal-title":"J Psychoactive Drugs"},{"key":"265_CR5","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard ED, Zarate CA. The role of dissociation in ketamine\u2019s antidepressant effects. Nat Commun. 2020;11:6431.","journal-title":"Nat Commun"},{"key":"265_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen CA, Rosenberg H. A review of the acute subjective effects of MDMA\/ecstasy. Addiction. 2006;101:933\u201347.","journal-title":"Addiction"},{"key":"265_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"265_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugpo.2017.07.017","volume":"49","author":"F BOHLING","year":"2017","unstructured":"Bohling F. Psychedelic pleasures: an affective understanding of the joys of tripping. Int J Drug Policy. 2017;49:133\u201343.","journal-title":"Int J Drug Policy"},{"key":"265_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","volume":"34","author":"JJ Breeksema","year":"2020","unstructured":"Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. 2020;34:925\u201346.","journal-title":"CNS Drugs"},{"key":"265_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017a;56:1543\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"265_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/02791072.2017.1344898","volume":"49","author":"T Brown","year":"2017","unstructured":"Brown T, Shao W, Ayub S, Chong D, Cornelius C. A Physician\u2019s Attempt to Self-Medicate Bipolar Depression with N, N-Dimethyltryptamine (DMT). J Psychoactive Drugs. 2017b;49:294\u20136.","journal-title":"J Psychoactive Drugs"},{"key":"265_CR12","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","volume":"359","author":"JG Bruhn","year":"2002","unstructured":"Bruhn JG, de Smet PA, El-Seedi HR, Beck O. Mescaline use for 5700 years. Lancet. 2002;359:1866.","journal-title":"Lancet"},{"key":"265_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pbr.2018.09.013","volume":"242","author":"T Calvey","year":"2018","unstructured":"Calvey T, Howells FM. An introduction to psychedelic neuroscience. Prog Brain Res. 2018;242:1\u201323.","journal-title":"Prog Brain Res"},{"key":"265_CR14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1021\/acschemneuro.8b00101","volume":"9","author":"LP Cameron","year":"2018","unstructured":"Cameron LP, Olson DE. Dark Classics in chemical neuroscience: N, N-Dimethyltryptamine (DMT). ACS Chem Neurosci. 2018;9:2344\u201357.","journal-title":"ACS Chem Neurosci"},{"key":"265_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, Maclean KA, Jesse R, Johnson MW, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30:1268\u201378.","journal-title":"J Psychopharmacol"},{"key":"265_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316\u201344.","journal-title":"Pharmacol Rev"},{"key":"265_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","volume":"78","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, Williams LT, Roseman L, Brugger S, de Meer I, Tanner M, Tyacke R, Wolff K, Sethi A, Bloomfield MA, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, Nutt DJ. The Effects of Acutely Administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry. 2015;78:554\u201362.","journal-title":"Biol Psychiatry"},{"key":"265_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"265_CR19","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187.","journal-title":"Sci Rep"},{"key":"265_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725\u201331.","journal-title":"J Psychopharmacol"},{"key":"265_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"265_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nrl.2011.07.003","volume":"30","author":"FJ CAROD-ARTAL","year":"2015","unstructured":"Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015;30:42\u20139.","journal-title":"Neurologia"},{"key":"265_CR23","first-page":"489","volume":"42","author":"FJ Carod-Artal","year":"2006","unstructured":"Carod-Artal FJ, Vazquez-Cabrera CB. Mescaline and the San Pedro cactus ritual: archaeological and ethnographic evidence in northern Peru. Rev Neurol. 2006;42:489\u201398.","journal-title":"Rev Neurol"},{"key":"265_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.739053","volume":"12","author":"J Castelhano","year":"2021","unstructured":"Castelhano J, Lima G, Teixeira M, Soares C, Pais M, Castelo-Branco M. The Effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies. Front Pharmacol. 2021;12: 739053.","journal-title":"Front Pharmacol"},{"key":"265_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/10503307.2017.1395922","volume":"29","author":"P Cuijpers","year":"2019","unstructured":"Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Hollon SD. Component studies of psychological treatments of adult depression: a systematic review and meta-analysis. Psychother Res. 2019;29:15\u201329.","journal-title":"Psychother Res"},{"key":"265_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/add.15154","volume":"116","author":"S Darke","year":"2021","unstructured":"Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of death related to the self-administration of ketamine. Addiction. 2021;116:339\u201345.","journal-title":"Addiction"},{"key":"265_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of Psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78:481\u20139.","journal-title":"JAMA Psychiat"},{"key":"265_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.724606","volume":"12","author":"CMH de Vos","year":"2021","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12: 724606.","journal-title":"Front Psychiatry"},{"key":"265_CR29","first-page":"CD011611","volume":"10","author":"RL Dean","year":"2021","unstructured":"Dean RL, Marquardt T, Hurducas C, Spyridi S, Barnes A, Smith R, Cowen PJ, McShane R, Hawton K, Malhi GS, Geddes J, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database Syst Rev. 2021;10:CD011611.","journal-title":"Cochrane Database Syst Rev"},{"key":"265_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1146\/annurev.pa.17.040177.003243","volume":"17","author":"JL DIAZ","year":"1977","unstructured":"Diaz JL. Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico. Annu Rev Pharmacol Toxicol. 1977;17:647\u201375.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"265_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1874467211666181010154139","volume":"12","author":"RJ Dinis-Oliveira","year":"2019","unstructured":"Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 2019;12:184\u201394.","journal-title":"Curr Mol Pharmacol"},{"key":"265_CR32","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, Muller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"265_CR33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017;56:1219\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"265_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51:189\u201398.","journal-title":"J Psychoactive Drugs"},{"key":"265_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/brain\/awab406","volume":"145","author":"MK Doss","year":"2022","unstructured":"Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, Barrett FS. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2022;145:441\u201356.","journal-title":"Brain"},{"key":"265_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1590\/1516-4446-2015-1701","volume":"38","author":"RG DosSantos","year":"2016","unstructured":"DosSantos RG, Osorio FL, Crippa JA, Hallak JE. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry. 2016;38:65\u201372.","journal-title":"Braz J Psychiatry"},{"key":"265_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/2045125316689030","volume":"7","author":"RGJC DosSantosBouso","year":"2017","unstructured":"DosSantosBouso RGJC, Hallak JEC. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Ther Adv Psychopharmacol. 2017;7:141\u201357.","journal-title":"Ther Adv Psychopharmacol"},{"key":"265_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/070674370505000703","volume":"50","author":"E DYCK","year":"2005","unstructured":"Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry. 2005;50:381\u20138.","journal-title":"Can J Psychiatry"},{"key":"265_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"265_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1017\/S0033291714002487","volume":"45","author":"AK Fett","year":"2015","unstructured":"Fett AK, Shergill SS, Krabbendam L. Social neuroscience in psychiatry: unravelling the neural mechanisms of social dysfunction. Psychol Med. 2015;45:1145\u201365.","journal-title":"Psychol Med"},{"key":"265_CR41","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1073\/pnas.1918477117","volume":"117","author":"M Forstmann","year":"2020","unstructured":"Forstmann M, Yudkin DA, Prosser AMB, Heller SM, Crockett MJ. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc Natl Acad Sci USA. 2020;117:2338\u201346.","journal-title":"Proc Natl Acad Sci USA"},{"key":"265_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","volume":"102","author":"RS GABLE","year":"2007","unstructured":"Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. 2007;102:24\u201334.","journal-title":"Addiction"},{"key":"265_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513\u201320.","journal-title":"J Nerv Ment Dis"},{"key":"265_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29:57\u201368.","journal-title":"J Psychopharmacol"},{"key":"265_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187:268\u201383.","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR46","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"265_CR47","volume-title":"Psychedelic drugs reconsidered","author":"L Grispoon","year":"1981","unstructured":"Grispoon L, Bakalar J. Psychedelic drugs reconsidered. New York: Lindesmith Center; 1981."},{"key":"265_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/1363461520983684","author":"N Gukasyan","year":"2021","unstructured":"Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psychiatry. 2021. https:\/\/doi.org\/10.1177\/1363461520983684.","journal-title":"Transcult Psychiatry"},{"key":"265_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","volume":"17","author":"J Hamill","year":"2019","unstructured":"Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. Curr Neuropharmacol. 2019;17:108\u201328.","journal-title":"Curr Neuropharmacol"},{"key":"265_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/02791072.1988.10472511","volume":"20","author":"G Hansen","year":"1988","unstructured":"Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs. 1988;20:419\u201325.","journal-title":"J Psychoactive Drugs"},{"key":"265_CR51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","volume":"4","author":"CJ Harmer","year":"2017","unstructured":"Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4:409\u201318.","journal-title":"Lancet Psychiatry"},{"key":"265_CR52","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamapsychiatry.2021.1207","volume":"78","author":"JC Harris","year":"2021","unstructured":"Harris JC. Psychedelic-assisted psychotherapy and Carl Jung\u2019s Red Book. JAMA Psychiatry. 2021;78:815.","journal-title":"JAMA Psychiatry"},{"key":"265_CR53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13181-016-0593-1","volume":"13","author":"CW Heise","year":"2017","unstructured":"Heise CW, Brooks DE. Ayahuasca exposure: descriptive analysis of calls to US poison control centers from 2005 to 2015. J Med Toxicol. 2017;13:245\u20138.","journal-title":"J Med Toxicol"},{"key":"265_CR54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bdi.13095","volume":"23","author":"HM Hendin","year":"2021","unstructured":"Hendin HM, Penn AD. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report. Bipolar Disord. 2021;23:733\u20135.","journal-title":"Bipolar Disord"},{"key":"265_CR55","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29:280\u20138.","journal-title":"J Psychopharmacol"},{"key":"265_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0269881117735685","volume":"32","author":"PS Hendricks","year":"2018","unstructured":"Hendricks PS, Crawford MS, Cropsey KL, Copes H, Sweat NW, Walsh Z, Pavela G. The relationships of classic psychedelic use with criminal behavior in the United States adult population. J Psychopharmacol. 2018;32:37\u201348.","journal-title":"J Psychopharmacol"},{"key":"265_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","volume":"30","author":"Hendricks, P. S.","year":"2018","unstructured":"Hendricks, P. S. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry. 2018;30:331\u201342.","journal-title":"Int Rev Psychiatry"},{"key":"265_CR58","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","volume":"32","author":"L Hermle","year":"1992","unstructured":"Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry. 1992;32:976\u201391.","journal-title":"Biol Psychiatry"},{"key":"265_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fpsyt.2020.00224","volume":"11","author":"K Heuschkel","year":"2020","unstructured":"Heuschkel K, Kuypers KPC. Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Front Psychiatry. 2020;11:224.","journal-title":"Front Psychiatry"},{"key":"265_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","volume":"11","author":"A Hofmann","year":"1979","unstructured":"Hofmann A. How LSD originated. J Psychedelic Drugs. 1979;11:53\u201360.","journal-title":"J Psychedelic Drugs"},{"key":"265_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tins.2010.10.004","volume":"34","author":"PE Holtzheimer","year":"2011","unstructured":"Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34:1\u20139.","journal-title":"Trends Neurosci"},{"key":"265_CR62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"265_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102206","volume":"44","author":"SKD Houle","year":"2021","unstructured":"Houle SKD, Evans D, Carter CA, Schlagenhauf P. Ayahuasca and the traveller: a scoping review of risks and possible benefits. Travel Med Infect Dis. 2021;44: 102206.","journal-title":"Travel Med Infect Dis"},{"key":"265_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","volume":"41","author":"N Hutten","year":"2020","unstructured":"Hutten N, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Feilding A, Ramaekers JG, Kuypers KPC. Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study. Eur Neuropsychopharmacol. 2020;41:81\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"key":"265_CR65","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","volume":"26","author":"DF Ionescu","year":"2018","unstructured":"Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, Deckersbach T. Ketamine-associated brain changes: a review of the neuroimaging literature. Harv Rev Psychiatry. 2018;26:320\u201339.","journal-title":"Harv Rev Psychiatry"},{"key":"265_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603\u201320.","journal-title":"J Psychopharmacol"},{"key":"265_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83\u2013102.","journal-title":"Pharmacol Ther"},{"key":"265_CR68","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/02698811211066714","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones GM, Nock MK. Lifetime use of MDMA\/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol. 2022a;36:57\u201365.","journal-title":"J Psychopharmacol"},{"key":"265_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/02698811211058923","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones GM, Nock MK. MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol. 2022b;36:46\u201356.","journal-title":"J Psychopharmacol"},{"key":"265_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/02698811211058933","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones GM, Nock MK. Psilocybin use is associated with lowered odds of crime arrests in US adults: a replication and extension. J Psychopharmacol. 2022c;36:66\u201373.","journal-title":"J Psychopharmacol"},{"key":"265_CR71","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","volume":"12","author":"G Jones","year":"2022","unstructured":"Jones G, Ricard JA, Lipson J, Nock MK. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep. 2022;12:4099.","journal-title":"Sci Rep"},{"key":"265_CR72","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/ALN.0000000000003577","volume":"133","author":"J Kamp","year":"2020","unstructured":"Kamp J, Olofsen E, Henthorn TK, van Velzen M, Niesters M, Dahan A. Ketamine pharmacokinetics. Anesthesiology. 2020;133:1192\u2013213.","journal-title":"Anesthesiology"},{"key":"265_CR73","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jpsychores.2015.03.009","volume":"78","author":"B Khoury","year":"2015","unstructured":"Khoury B, Sharma M, Rush SE, Fournier C. Mindfulness-based stress reduction for healthy individuals: a meta-analysis. J Psychosom Res. 2015;78:519\u201328.","journal-title":"J Psychosom Res"},{"key":"265_CR74","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/7854_2016_461","volume":"36","author":"M Kometer","year":"2018","unstructured":"Kometer M, Vollenweider FX. Serotonergic hallucinogen-induced visual perceptual alterations. Curr Top Behav Neurosci. 2018;36:257\u201382.","journal-title":"Curr Top Behav Neurosci"},{"key":"265_CR75","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78:572\u201381.","journal-title":"Biol Psychiatry"},{"key":"265_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","volume":"11","author":"R Kraehenmann","year":"2016","unstructured":"Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin. 2016;11:53\u201360.","journal-title":"Neuroimage Clin"},{"key":"265_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PLoS ONE. 2013;8: e63972.","journal-title":"PLoS ONE"},{"key":"265_CR78","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1176\/ajp.138.11.1508","volume":"138","author":"CR Lake","year":"1981","unstructured":"Lake CR, Stirba AL, Kinneman RE, Carlson B, Holloway HC. Mania associated with LSD ingestion. Am J Psychiatry. 1981;138:1508\u20139.","journal-title":"Am J Psychiatry"},{"key":"265_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.psychotherapy.1969.23.1.4","volume":"23","author":"H LEUNER","year":"1969","unstructured":"Leuner H. Guided affective imagery (GAI). A method of intensive psychotherapy. Am J Psychother. 1969;23:4\u201321.","journal-title":"Am J Psychother"},{"key":"265_CR80","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1056\/NEJMe2102835","volume":"384","author":"JA Lieberman","year":"2021","unstructured":"Lieberman JA. Back to the Future\u2014The therapeutic potential of psychedelic drugs. N Engl J Med. 2021;384:1460\u20131.","journal-title":"N Engl J Med"},{"key":"265_CR81","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AS, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh ZS, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-Mckenney KM, Gray JA, Olson DE. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"265_CR82","doi-asserted-by":"publisher","first-page":"9856","DOI":"10.1523\/JNEUROSCI.21-24-09856.2001","volume":"21","author":"R Martin-Ruiz","year":"2001","unstructured":"Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001;21:9856\u201366.","journal-title":"J Neurosci"},{"key":"265_CR83","volume-title":"Psychedelic Art","author":"REL Masters","year":"1968","unstructured":"Masters REL, Houston J. Psychedelic Art. New York: Grove Press; 1968."},{"key":"265_CR84","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","volume":"264","author":"DS Mathai","year":"2020","unstructured":"Mathai DS, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J Affect Disord. 2020;264:123\u20139.","journal-title":"J Affect Disord"},{"key":"265_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.868103","volume":"13","author":"DS Mathai","year":"2022","unstructured":"Mathai DS, Mora V, Garcia-Romeu A. Toward synergies of ketamine and psychotherapy. Front Psychol. 2022;13: 868103.","journal-title":"Front Psychol"},{"key":"265_CR86","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463.","journal-title":"Nat Rev Drug Discov"},{"key":"265_CR87","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","volume":"276","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Lee Y, Tamura JK, Iacobucci M, Phan L, Nasri F, Singhal N, Wong ER, Subramaniapillai M, Mansur R, Ho R, Lam RW, Rosenblat JD. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord. 2020;276:576\u201384.","journal-title":"J Affect Disord"},{"key":"265_CR88","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1902174116","volume":"116","author":"MJ Miller","year":"2019","unstructured":"Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proc Natl Acad Sci USA. 2019;116:11207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"265_CR89","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3389\/fpsyg.2018.01475","volume":"9","author":"R Milliere","year":"2018","unstructured":"Milliere R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, meditation, and self-consciousness. Front Psychol. 2018;9:1475.","journal-title":"Front Psychol"},{"key":"265_CR90","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot\u2019Alora GM, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"265_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.695335","volume":"12","author":"OM Mollaahmetoglu","year":"2021","unstructured":"Mollaahmetoglu OM, Keeler J, Ashbullby KJ, Ketzitzidou-Argyri E, Grabski M, Morgan CJA. \u201cThis Is Something That Changed My Life\u201d: A qualitative study of patients\u2019 experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12: 695335.","journal-title":"Front Psychiatry"},{"key":"265_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.54","volume":"7","author":"F Mueller","year":"2017","unstructured":"Mueller F, Lenz C, Dolder PC, Harder S, Schmid Y, Lang UE, Liechti ME, Borgwardt S. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7: e1084.","journal-title":"Transl Psychiatry"},{"key":"265_CR93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","volume":"95","author":"L Muetzelfeldt","year":"2008","unstructured":"Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"265_CR94","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","volume":"18","author":"F Muller","year":"2018","unstructured":"Muller F, Dolder PC, Schmidt A, Liechti ME, Borgwardt S. Altered network hub connectivity after acute LSD administration. Neuroimage Clin. 2018;18:694\u2013701.","journal-title":"Neuroimage Clin"},{"key":"265_CR95","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1524-2794","volume":"54","author":"SM Nayak","year":"2021","unstructured":"Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54:240\u20135.","journal-title":"Pharmacopsychiatry"},{"key":"265_CR96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355.","journal-title":"Pharmacol Rev"},{"key":"265_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","volume":"284","author":"DE Nichols","year":"2018","unstructured":"Nichols DE, Grob CS. Is LSD toxic? Forensic Sci Int. 2018;284:141\u20135.","journal-title":"Forensic Sci Int"},{"key":"265_CR98","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1310-3990","volume":"54","author":"DE Nichols","year":"2021","unstructured":"Nichols DE, Walter H. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021;54:151\u201366.","journal-title":"Pharmacopsychiatry"},{"key":"265_CR99","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"DE Nichols","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101:209\u201319.","journal-title":"Clin Pharmacol Ther"},{"key":"265_CR100","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","volume":"210","author":"MM Nour","year":"2017","unstructured":"Nour MM, Carhart-Harris RL. Psychedelics and the science of self-experience. Br J Psychiatry. 2017;210:177\u20139.","journal-title":"Br J Psychiatry"},{"key":"265_CR101","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiat. 2021;78:121\u20132.","journal-title":"JAMA Psychiat"},{"key":"265_CR102","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.euroneuro.2011.05.004","volume":"21","author":"D Nutt","year":"2011","unstructured":"Nutt D, Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol. 2011;21:495\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"265_CR103","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","volume":"66","author":"H OSMOND","year":"1957","unstructured":"Osmond H. A review of the clinical effects of psychotomimetic agents. Ann NY Acad Sci. 1957;66:418\u201334.","journal-title":"Ann NY Acad Sci"},{"key":"265_CR104","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"FDEL Osorio","year":"2015","unstructured":"Osorio FDEL, Sanches RF, Macedo LR, Santos RG, Maia-De-oliveira JP, Wichert-Ana L, Araujo DB, Riba J, Crippa JA, Hallak JE. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37:13\u201320.","journal-title":"Braz J Psychiatry"},{"key":"265_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"F Palhano-Fontes","year":"2015","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JA, Hallak JE, Ribeiro S, de Araujo DB. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE. 2015;10: e0118143.","journal-title":"PLoS ONE"},{"key":"265_CR106","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osorio FL, Sanches R, dos Santos RG, Tofoli LF, de Silveira G, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvao-Coelho NL, Lobao-Soares B, Hallak JEC, Arcoverde E, Maia-De-oliveira JP, Araujo DB. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655.","journal-title":"Psychol Med"},{"key":"265_CR107","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/0269881120909409","volume":"34","author":"L Pasquini","year":"2020","unstructured":"Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol. 2020;34:623\u201335.","journal-title":"J Psychopharmacol"},{"key":"265_CR108","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357\u201364.","journal-title":"Addict Biol"},{"key":"265_CR109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14:295\u2013314.","journal-title":"CNS Neurosci Ther"},{"key":"265_CR110","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55:1059\u201377.","journal-title":"Clin Pharmacokinet"},{"key":"265_CR111","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00213-007-0706-2","volume":"192","author":"EB Perry","year":"2007","unstructured":"Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O\u2019Donnell E, Krystal JH, D\u2019Souza C, YALE KETAMINE STUDY G. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192:253\u201360.","journal-title":"Psychopharmacology (Berl)"},{"key":"265_CR112","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","volume":"11","author":"R Petranker","year":"2020","unstructured":"Petranker R, Anderson T, Farb N. Psychedelic research and the need for transparency: polishing Alice\u2019s looking glass. Front Psychol. 2020;11:1681.","journal-title":"Front Psychol"},{"key":"265_CR113","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","volume":"36","author":"KH Preller","year":"2018","unstructured":"Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. 2018;36:221\u201356.","journal-title":"Curr Top Behav Neurosci"},{"key":"265_CR114","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1073\/pnas.1524187113","volume":"113","author":"KH Preller","year":"2016","unstructured":"Preller KH, Pokorny T, Hock A, Kraehenmann R, Stampfli P, Seifritz E, Scheidegger M, Vollenweider FX. Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A. 2016;113:5119\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"265_CR115","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1523\/JNEUROSCI.1939-17.2018","volume":"38","author":"KH Preller","year":"2018","unstructured":"Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38:3603\u201311.","journal-title":"J Neurosci"},{"key":"265_CR116","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.103.049882","volume":"306","author":"J Riba","year":"2003","unstructured":"Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306:73\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"265_CR117","doi-asserted-by":"publisher","first-page":"213","DOI":"10.31887\/DCNS.2013.15.2\/lripoll","volume":"15","author":"RIPOLL, L. H.","year":"2013","unstructured":"Ripoll L. H. Psychopharmacologic treatment of borderline personality disorder. Dialogues Clin Neurosci. 2013;15:213\u201324.","journal-title":"Dialogues Clin Neurosci"},{"key":"265_CR118","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2017;8:974.","journal-title":"Front Pharmacol"},{"key":"265_CR119","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165\u201380.","journal-title":"J Psychopharmacol"},{"key":"265_CR120","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016;30:1220\u20139.","journal-title":"J Psychopharmacol"},{"key":"265_CR121","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de LimaOsorio QF, Santos RG, Macedo LR, De-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, Hallak JE. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77\u201381.","journal-title":"J Clin Psychopharmacol"},{"key":"265_CR122","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36:258\u201372.","journal-title":"J Psychopharmacol"},{"key":"265_CR123","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/164_2018_113","volume":"252","author":"LD Simmler","year":"2018","unstructured":"Simmler LD, Liechti ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. Handb Exp Pharmacol. 2018;252:143\u201364.","journal-title":"Handb Exp Pharmacol"},{"key":"265_CR124","doi-asserted-by":"publisher","first-page":"14427","DOI":"10.1038\/s41598-021-93787-4","volume":"11","author":"O Simonsson","year":"2021","unstructured":"Simonsson O, Osika W, Carhart-Harris R, Hendricks PS. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep. 2021a;11:14427.","journal-title":"Sci Rep"},{"key":"265_CR125","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269881121996863","volume":"35","author":"O Simonsson","year":"2021","unstructured":"Simonsson O, Sexton JD, Hendricks PS. Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol. 2021b;35:447\u201352.","journal-title":"J Psychopharmacol"},{"key":"265_CR126","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","volume":"9","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Kometer M, Scheidegger M, Krahenmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9:14914.","journal-title":"Sci Rep"},{"key":"265_CR127","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0269881116628430","volume":"30","author":"J Speth","year":"2016","unstructured":"Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, Carhart-Harris RL. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. 2016;30:344\u201353.","journal-title":"J Psychopharmacol"},{"key":"265_CR128","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1176\/ajp.151.11.1642","volume":"151","author":"AL Stoll","year":"1994","unstructured":"Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994;151:1642\u20135.","journal-title":"Am J Psychiatry"},{"key":"265_CR129","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","volume":"235","author":"JB Stroud","year":"2018","unstructured":"Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology. 2018;235:459\u201366.","journal-title":"Psychopharmacology"},{"key":"265_CR130","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/0269881106060764","volume":"20","author":"HR Sumnall","year":"2006","unstructured":"Sumnall HR, Cole JC, Jerome L. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol. 2006;20:670\u201382.","journal-title":"J Psychopharmacol"},{"key":"265_CR131","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"J Swainson","year":"2021","unstructured":"Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Reseau Canadien Pour Les Traitements De L\u2019humeur Et De L\u2019anxiete (Canmat) Concernant L\u2019utilisation De La Ketamine Racemique Chez Les Adultes Souffrant De Trouble Depressif Majeur. Can J Psychiatry. 2021;66:113\u201325.","journal-title":"Can J Psychiatry"},{"key":"265_CR132","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40345-014-0020-y","volume":"3","author":"AG Szmulewicz","year":"2015","unstructured":"Szmulewicz AG, Valerio MP, Smith JM. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord. 2015;3:4.","journal-title":"Int J Bipolar Disord"},{"key":"265_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.549080","volume":"12","author":"J Vankawala","year":"2021","unstructured":"Vankawala J, Naples G, Avila-Quintero VJ, Ramirez KL, Flores JM, Bloch MH, Dwyer JB. Meta-Analysis: hemodynamic responses to sub-anesthetic doses of ketamine in patients with psychiatric disorders. Front Psychiatry. 2021;12: 549080.","journal-title":"Front Psychiatry"},{"key":"265_CR134","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1176\/appi.ajp.2014.13111501","volume":"171","author":"A Viktorin","year":"2014","unstructured":"Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK, Landen M. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171:1067\u201373.","journal-title":"Am J Psychiatry"},{"key":"265_CR135","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bja.2018.03.011","volume":"121","author":"PE Vlisides","year":"2018","unstructured":"Vlisides PE, Bel-Bahar T, Nelson A, Chilton K, Smith E, Janke E, Tarnal V, Picton P, Harris RE, Mashour GA. Subanaesthetic ketamine and altered states of consciousness in humans. Br J Anaesth. 2018;121:249\u201359.","journal-title":"Br J Anaesth"},{"key":"265_CR136","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","volume":"56","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56:495\u2013507.","journal-title":"Brain Res Bull"},{"key":"265_CR137","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"265_CR138","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324.","journal-title":"Nat Rev Neurosci"},{"key":"265_CR139","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16:357\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"265_CR140","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897\u2013902.","journal-title":"NeuroReport"},{"key":"265_CR141","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2013a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20:424\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"265_CR142","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","volume":"3","author":"FX Vollenweiderf","year":"2001","unstructured":"Vollenweiderf FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3:265\u201379.","journal-title":"Dialogues Clin Neurosci"},{"key":"265_CR143","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/01.jcp.0000237950.65517.be","volume":"26","author":"K Wada","year":"2006","unstructured":"Wada K, Sasaki T, Jitsuiki H, Yoshimura Y, Erabi H, Hada Y, Yamashita M. Manic\/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol. 2006;26:512\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"265_CR144","volume-title":"The wondrous mushroom: mycolaltry in Mesoamerica","author":"RG Wasson","year":"1980","unstructured":"Wasson RG. The wondrous mushroom: mycolaltry in Mesoamerica. New York: McGrw-Hill; 1980."},{"key":"265_CR145","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","volume":"15","author":"R Watts","year":"2020","unstructured":"Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci. 2020;15:92\u2013102.","journal-title":"J Contextual Behav Sci"},{"key":"265_CR146","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris RL. Patients\u2019 accounts of increased \u201cConnectedness\u201d and \u201cAcceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017;57:520\u201364.","journal-title":"J Humanist Psychol"},{"key":"265_CR147","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/02698811211073758","volume":"36","author":"M Wolff","year":"2022","unstructured":"Wolff M, Mertens LJ, Walter M, Enge S, Evens R. The Acceptance\/Avoidance-Promoting Experiences Questionnaire (APEQ): a theory-based approach to psychedelic drugs\u2019 effects on psychological flexibility. J Psychopharmacol. 2022;36:387\u2013408.","journal-title":"J Psychopharmacol"},{"key":"265_CR148","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","volume":"134","author":"J Xiong","year":"2021","unstructured":"Xiong J, Lipsitz O, Chen-Li D, Rosenblat JD, Rodrigues NB, Carvalho I, Lui LMW, Gill H, Narsi F, Mansur RB, Lee Y, McIntyre RS. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021;134:57\u201368.","journal-title":"J Psychiatr Res"},{"key":"265_CR149","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","volume":"78","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Yaden ME, Griffiths RR. Psychedelics in psychiatry\u2014Keeping the Renaissance from going off the rails. JAMA Psychiat. 2021;78:469\u201370.","journal-title":"JAMA Psychiat"},{"key":"265_CR150","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"265_CR151","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"265_CR152","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21r14057","author":"RJ Zeifman","year":"2022","unstructured":"Zeifman RJ, Yu D, Singhal N, Wang G, Nayak SM, Weissman CR. Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials. J Clin Psychiatry. 2022. https:\/\/doi.org\/10.4088\/JCP.21r14057.","journal-title":"J Clin Psychiatry"},{"key":"265_CR153","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00115-019-0728-0","volume":"90","author":"N Zellner","year":"2019","unstructured":"Zellner N, Zellner T, Warninghoff J. Ayahuasca-induced psychosis in a patient with bipolar disorder. Nervenarzt. 2019;90:1154\u20135.","journal-title":"Nervenarzt"},{"key":"265_CR154","unstructured":"NCT05065294. Clinicaltrials.gov. 2022. National Library of Medicine: Rockville Pike, USA. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05065294."},{"key":"265_CR155","unstructured":"Hofmann A. 2012. LSD - Mein Sorgenkind. Die Entdeckung einer \"Wunderdroge\", Klett-Cotta Literatur."},{"key":"265_CR156","unstructured":"Huxley A. 1959. The doors of perception; and: Heaven and hell, Penguin Books in association with Chatto & Windus."},{"key":"265_CR157","unstructured":"Sandoz. Delysid LSD25 D-lysergic acid dieethylamide tartrate. 1964. Sandoz House: London."},{"key":"265_CR158","unstructured":"UN. Convention on Psychotropic Substances. UN General Assembly Doc. No. A\/RES\/3443. 1971. United Nations Organization: New York City, USA. Available: https:\/\/www.unodc.org\/pdf\/convention_1971_en.pdf."},{"key":"265_CR159","unstructured":"WHO. Model list of essential medicines. 22nd List, 2021. World Health Organization: Geneva, Switzerland. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02."}],"container-title":["International Journal of Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-022-00265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40345-022-00265-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-022-00265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:05:23Z","timestamp":1656997523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalbipolardisorders.springeropen.com\/articles\/10.1186\/s40345-022-00265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1186\/s40345-022-00265-5","relation":{},"ISSN":["2194-7511"],"issn-type":[{"value":"2194-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Bosch has received honoraria as a lecturer from Janssen-Cilag. He declares no further conflict of interest. Dr. Halm declares no conflict of interest. Prof. Dr. Seifritz has received honoraria as a lecturer from Janssen-Cilag. He declares no further conflict of interest.\nJanssen-Cilag is manufacturing and marketing the esketamine nasal spray Spravato for the treatment of therapy-resistant depression.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bosch has received honoraria as a lecturer from Janssen-Cilag. He declares no further conflict of interest. Dr. Halm declares no conflict of interest. Prof. Dr. Seifritz has received honoraria as a lecturer from Janssen-Cilag. He declares no further conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}